SlideShare ist ein Scribd-Unternehmen logo
1 von 14
TUBERCULOSIS
WHO guideline 2010
Case definition
• TB suspected :
• productive cough > 2 weeks
• Constitual symptom : loss of apetite , weight loss , fever night
• Respiratory symptom :shortness of breath ,chest pain , hemoptysis
• Case of TB
• Definite case + treat TB
• Definite case of TB
• ≥1 sputum AFB +ve or C/S or molecular lne probe assay
Treatment
• First line antituberculosis drugs
• Isoniazid 5MKD – max < 300mg/day
• Rifampicin 10MKD – max <600mg/day
• Streptomycin 15MKD
• Age >60 yrs
• BW < 50kgs

may not tolerate dose >500-750mg/day
may not tolerate dose >500-750mg/day

• Ethambutol 15MKD
• Pyrazinamide 25MKD(20-30 MKD)
Treatment regimen
• New patient :
• 2IRZE/4IR standard TB meningitis—streptomycin replace to etham
• High incidence INH resist : 2IRZE/4IRE
• AFB+ after 2IRZE – repeat sputum 3rd month AFB+ : DST
• Previous treatment:
• Default /relapse : 2IRZES/1IRZE/5IRE
• Treatment failure : empirical MDR regimen

HIV CD4< 200cell/cc sputum AFB + ส่ง DSTทุก
ราย
Pyridoxine 10mg/day– INH S/E
Treatment regimen
• Extrapulmonary tuberculosis
• TB meningitis
• Extended regimen
• Change etham to streptomycin
• Add dexa if not wonder drug resistance
• TB bone and joint
• Extended regimen
Treatment regimen
• HIV co-infection
• Start anti TB drug and start ARV within 8 wks
• ARV regimen

3TC/AZT
3TC/TDF

EFV
NVP
Follow up
• 2IRZE/4IR regimen
• Sputum AFB at 2nd , 5th , 6th month
• If 2nd month sputum AFB+ repeat at 3rd month
• If 3rd , 5th ,6th month sputum AFB + --- DST
• 2IRZES/1IRZE/5IREregimen
• Sputum AFB at 3rd , 5th , 8th month if +ve -- DST
Follow up
• Sputum AFB +ve after intensive phase
• Poor adherance and compliance
• Low quallity antiTB drug
• Lower than standard dose treatment
• Numerous TB load α extensive cavitation
• MDR TB
• Sputum AFB +ve but not alive
Adverse drug reaction
• Minor adverse effect
• Close observe clinical , symptom base approach
• Major adverse effect
• Stop antiTB drug +admit for observe clinical
Cutaneous reaction
• No skin rash but isching – antihistamine+skin moisturizing
• Skin rash
• stop anti TB drug and rechallange when full recovery
• INH / rifam low dose and increase dose
Drug induced hepatitis
• Hepatitis : INH , PZA , rifampicin
• Jaundice : rifampicin
• Rechallange
• Stop antiTB drug and start EOS regimen for 2wks
• If continuation phase
• INH not include : 6-9 RZE

• Start rifampicin 3-7days and 2nd INH if no hepatitis
• PZA include – IRZE
• PZA not include –2IRES/6IR
• Rifam+PZA not include – 2IES/10IE
• INH+rifam not include – 18-24EOS
Pregnancy and breast feeding
• 2IRZE/4IR
• Streptomycin : contraindication ototoxicity in fetus
• INH prophylaxis in children for 6 months
• Pyridoxine supplement
Liver disease
• 2 hepatotoxic drugs
• 9IRE
• 2IRSE/6IR
• 6-9RZE
• 1 hepatotoxic drug
• 2IES/10IE
• No hepatotoxic drug
• 18-24 EOS
Renal disease
• 2IRZE/4IR
• INH , rifampicin – no adjust dose
• Ethambutal , PZA – 3 times/ wk + adjust dose
• Adjust dose
• Ethambutal 15 Mg//kg/time
• PZA
25 Mg/kg/time

Pyridoxine 15-50mg/day for INH

Weitere ähnliche Inhalte

Was ist angesagt?

Intro to antibiotics ii clinical pearls 72816
Intro to antibiotics ii  clinical pearls 72816Intro to antibiotics ii  clinical pearls 72816
Intro to antibiotics ii clinical pearls 72816
Jedrek Wosik, MD
 
Factm malaria 1
Factm malaria 1Factm malaria 1
Factm malaria 1
Tim Inglis
 
Tuberculin n scalp vein needle
Tuberculin n scalp vein needleTuberculin n scalp vein needle
Tuberculin n scalp vein needle
Pratik Kumar
 

Was ist angesagt? (20)

Management of malaria 2
Management of malaria 2Management of malaria 2
Management of malaria 2
 
Intro to antibiotics ii clinical pearls 72816
Intro to antibiotics ii  clinical pearls 72816Intro to antibiotics ii  clinical pearls 72816
Intro to antibiotics ii clinical pearls 72816
 
SCABIES CASE PRESENTATION
SCABIES CASE PRESENTATIONSCABIES CASE PRESENTATION
SCABIES CASE PRESENTATION
 
Endocarditis infecciosa
Endocarditis infecciosaEndocarditis infecciosa
Endocarditis infecciosa
 
case prensentation on Dengue and thrombocytopenia
case prensentation on Dengue and thrombocytopeniacase prensentation on Dengue and thrombocytopenia
case prensentation on Dengue and thrombocytopenia
 
TB MENINGITIS CASE PRESENTATION
 TB MENINGITIS CASE PRESENTATION  TB MENINGITIS CASE PRESENTATION
TB MENINGITIS CASE PRESENTATION
 
Case Representation on Typhoid
Case Representation on TyphoidCase Representation on Typhoid
Case Representation on Typhoid
 
Factm malaria 1
Factm malaria 1Factm malaria 1
Factm malaria 1
 
Case presentation on parkinson's disease
Case presentation on parkinson's diseaseCase presentation on parkinson's disease
Case presentation on parkinson's disease
 
Fever - Approach to Paediatric Patient
Fever - Approach to Paediatric PatientFever - Approach to Paediatric Patient
Fever - Approach to Paediatric Patient
 
WHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis managementWHO and RNTCP guidelines - Tuberculosis management
WHO and RNTCP guidelines - Tuberculosis management
 
Case Presentation on Appendicitis.
Case Presentation on Appendicitis.Case Presentation on Appendicitis.
Case Presentation on Appendicitis.
 
Drug profiles of Vancomycin, Prednisone and Salbutamol
Drug profiles of Vancomycin, Prednisone and SalbutamolDrug profiles of Vancomycin, Prednisone and Salbutamol
Drug profiles of Vancomycin, Prednisone and Salbutamol
 
Case on Urosepsis
Case on UrosepsisCase on Urosepsis
Case on Urosepsis
 
Parkinson's Disease
Parkinson's Disease Parkinson's Disease
Parkinson's Disease
 
case study - Urinary tract infection with diabetes mellitus
case study - Urinary tract infection with  diabetes mellitus case study - Urinary tract infection with  diabetes mellitus
case study - Urinary tract infection with diabetes mellitus
 
Severe asthma update and case discussion 20200603
Severe asthma update and case discussion 20200603Severe asthma update and case discussion 20200603
Severe asthma update and case discussion 20200603
 
9. a case study on uti and iron deficiency anaemia
9. a case study on uti and iron deficiency anaemia9. a case study on uti and iron deficiency anaemia
9. a case study on uti and iron deficiency anaemia
 
Tuberculin n scalp vein needle
Tuberculin n scalp vein needleTuberculin n scalp vein needle
Tuberculin n scalp vein needle
 
Aiims covid protocol
Aiims covid protocolAiims covid protocol
Aiims covid protocol
 

Andere mochten auch (6)

Anti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case StudyAnti tuberculosis drug - induced hepatitis – A Case Study
Anti tuberculosis drug - induced hepatitis – A Case Study
 
Case study
Case studyCase study
Case study
 
Diagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary TuberculosisDiagnosis of Pulmonary Tuberculosis
Diagnosis of Pulmonary Tuberculosis
 
Pulmonary Tuberculosis Presentation
Pulmonary Tuberculosis PresentationPulmonary Tuberculosis Presentation
Pulmonary Tuberculosis Presentation
 
TB drugs and ADR
TB drugs and ADRTB drugs and ADR
TB drugs and ADR
 
Interpretation of Liver Function Tests
Interpretation of Liver Function TestsInterpretation of Liver Function Tests
Interpretation of Liver Function Tests
 

Ähnlich wie Tuberculosis

Case Study
Case StudyCase Study
Case Study
su myat
 

Ähnlich wie Tuberculosis (20)

TB mangement in special situations
TB mangement in special situationsTB mangement in special situations
TB mangement in special situations
 
TB MENINGITIS and anti tuberculous drugs
TB MENINGITIS and anti tuberculous drugsTB MENINGITIS and anti tuberculous drugs
TB MENINGITIS and anti tuberculous drugs
 
Chinmoy tb presentation
Chinmoy tb presentationChinmoy tb presentation
Chinmoy tb presentation
 
Anti tuberculosis treatment regimens
Anti tuberculosis treatment regimensAnti tuberculosis treatment regimens
Anti tuberculosis treatment regimens
 
CASE PRESENTATION ON ACUTE PANCREATITIS
CASE PRESENTATION ON ACUTE PANCREATITISCASE PRESENTATION ON ACUTE PANCREATITIS
CASE PRESENTATION ON ACUTE PANCREATITIS
 
Antitubercular drugs
Antitubercular drugsAntitubercular drugs
Antitubercular drugs
 
Non resistant tuberculosis
Non resistant tuberculosisNon resistant tuberculosis
Non resistant tuberculosis
 
Case Study
Case StudyCase Study
Case Study
 
Guest Lecture: June 2013; Clinical manifestations of tuberculosis and its man...
Guest Lecture: June 2013; Clinical manifestations of tuberculosis and its man...Guest Lecture: June 2013; Clinical manifestations of tuberculosis and its man...
Guest Lecture: June 2013; Clinical manifestations of tuberculosis and its man...
 
Management of COVID 19 in Adults
Management of COVID 19 in AdultsManagement of COVID 19 in Adults
Management of COVID 19 in Adults
 
Potts spine management part 2
Potts spine management part 2Potts spine management part 2
Potts spine management part 2
 
Immune check point inhibitors and adverse effects
Immune check point inhibitors and adverse effectsImmune check point inhibitors and adverse effects
Immune check point inhibitors and adverse effects
 
adverse effects of ATT.pptx
adverse effects of ATT.pptxadverse effects of ATT.pptx
adverse effects of ATT.pptx
 
Recent changes in RNTCP Guidelines
Recent changes in RNTCP Guidelines    Recent changes in RNTCP Guidelines
Recent changes in RNTCP Guidelines
 
Tuberculosis treatment.pptx
Tuberculosis treatment.pptxTuberculosis treatment.pptx
Tuberculosis treatment.pptx
 
Latest edition tog updates 3
Latest edition tog updates 3Latest edition tog updates 3
Latest edition tog updates 3
 
MDR TB ppt.pptx
MDR TB  ppt.pptxMDR TB  ppt.pptx
MDR TB ppt.pptx
 
Known case of type 2 Diabetes Mellitus with hypertension with urosepsis
Known case of type 2 Diabetes Mellitus with hypertension with urosepsisKnown case of type 2 Diabetes Mellitus with hypertension with urosepsis
Known case of type 2 Diabetes Mellitus with hypertension with urosepsis
 
Regimens, prophylaxis of tb and dots
Regimens, prophylaxis of tb and dotsRegimens, prophylaxis of tb and dots
Regimens, prophylaxis of tb and dots
 
Influenza ppt(kannan) (1)
Influenza ppt(kannan)  (1)Influenza ppt(kannan)  (1)
Influenza ppt(kannan) (1)
 

Kürzlich hochgeladen

Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
KarakKing
 

Kürzlich hochgeladen (20)

On National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan FellowsOn National Teacher Day, meet the 2024-25 Kenan Fellows
On National Teacher Day, meet the 2024-25 Kenan Fellows
 
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
80 ĐỀ THI THỬ TUYỂN SINH TIẾNG ANH VÀO 10 SỞ GD – ĐT THÀNH PHỐ HỒ CHÍ MINH NĂ...
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Single or Multiple melodic lines structure
Single or Multiple melodic lines structureSingle or Multiple melodic lines structure
Single or Multiple melodic lines structure
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptxOn_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
On_Translating_a_Tamil_Poem_by_A_K_Ramanujan.pptx
 
Application orientated numerical on hev.ppt
Application orientated numerical on hev.pptApplication orientated numerical on hev.ppt
Application orientated numerical on hev.ppt
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
SOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning PresentationSOC 101 Demonstration of Learning Presentation
SOC 101 Demonstration of Learning Presentation
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptxExploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
Exploring_the_Narrative_Style_of_Amitav_Ghoshs_Gun_Island.pptx
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
REMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptxREMIFENTANIL: An Ultra short acting opioid.pptx
REMIFENTANIL: An Ultra short acting opioid.pptx
 
Salient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functionsSalient Features of India constitution especially power and functions
Salient Features of India constitution especially power and functions
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 

Tuberculosis

  • 2. Case definition • TB suspected : • productive cough > 2 weeks • Constitual symptom : loss of apetite , weight loss , fever night • Respiratory symptom :shortness of breath ,chest pain , hemoptysis • Case of TB • Definite case + treat TB • Definite case of TB • ≥1 sputum AFB +ve or C/S or molecular lne probe assay
  • 3. Treatment • First line antituberculosis drugs • Isoniazid 5MKD – max < 300mg/day • Rifampicin 10MKD – max <600mg/day • Streptomycin 15MKD • Age >60 yrs • BW < 50kgs may not tolerate dose >500-750mg/day may not tolerate dose >500-750mg/day • Ethambutol 15MKD • Pyrazinamide 25MKD(20-30 MKD)
  • 4. Treatment regimen • New patient : • 2IRZE/4IR standard TB meningitis—streptomycin replace to etham • High incidence INH resist : 2IRZE/4IRE • AFB+ after 2IRZE – repeat sputum 3rd month AFB+ : DST • Previous treatment: • Default /relapse : 2IRZES/1IRZE/5IRE • Treatment failure : empirical MDR regimen HIV CD4< 200cell/cc sputum AFB + ส่ง DSTทุก ราย Pyridoxine 10mg/day– INH S/E
  • 5. Treatment regimen • Extrapulmonary tuberculosis • TB meningitis • Extended regimen • Change etham to streptomycin • Add dexa if not wonder drug resistance • TB bone and joint • Extended regimen
  • 6. Treatment regimen • HIV co-infection • Start anti TB drug and start ARV within 8 wks • ARV regimen 3TC/AZT 3TC/TDF EFV NVP
  • 7. Follow up • 2IRZE/4IR regimen • Sputum AFB at 2nd , 5th , 6th month • If 2nd month sputum AFB+ repeat at 3rd month • If 3rd , 5th ,6th month sputum AFB + --- DST • 2IRZES/1IRZE/5IREregimen • Sputum AFB at 3rd , 5th , 8th month if +ve -- DST
  • 8. Follow up • Sputum AFB +ve after intensive phase • Poor adherance and compliance • Low quallity antiTB drug • Lower than standard dose treatment • Numerous TB load α extensive cavitation • MDR TB • Sputum AFB +ve but not alive
  • 9. Adverse drug reaction • Minor adverse effect • Close observe clinical , symptom base approach • Major adverse effect • Stop antiTB drug +admit for observe clinical
  • 10. Cutaneous reaction • No skin rash but isching – antihistamine+skin moisturizing • Skin rash • stop anti TB drug and rechallange when full recovery • INH / rifam low dose and increase dose
  • 11. Drug induced hepatitis • Hepatitis : INH , PZA , rifampicin • Jaundice : rifampicin • Rechallange • Stop antiTB drug and start EOS regimen for 2wks • If continuation phase • INH not include : 6-9 RZE • Start rifampicin 3-7days and 2nd INH if no hepatitis • PZA include – IRZE • PZA not include –2IRES/6IR • Rifam+PZA not include – 2IES/10IE • INH+rifam not include – 18-24EOS
  • 12. Pregnancy and breast feeding • 2IRZE/4IR • Streptomycin : contraindication ototoxicity in fetus • INH prophylaxis in children for 6 months • Pyridoxine supplement
  • 13. Liver disease • 2 hepatotoxic drugs • 9IRE • 2IRSE/6IR • 6-9RZE • 1 hepatotoxic drug • 2IES/10IE • No hepatotoxic drug • 18-24 EOS
  • 14. Renal disease • 2IRZE/4IR • INH , rifampicin – no adjust dose • Ethambutal , PZA – 3 times/ wk + adjust dose • Adjust dose • Ethambutal 15 Mg//kg/time • PZA 25 Mg/kg/time Pyridoxine 15-50mg/day for INH